MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-11-2026
Organovo Holdings Interest Expense 2011-2026 | ONVO
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Organovo Holdings
| 2025 | 2024 | 2023 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 6 K | 1.54 M | - | -12 K | - | - | 1 K | 13 K | - | 1.09 M | 2.07 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.07 M | -12 K | 671 K |
Quarterly Interest Expense Organovo Holdings
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 25 K | 25 K | - | - | - | - | - | 1.19 M | 1.45 M | 267 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3 K | - | - | - | - | 13 K | - | 13 K | 13 K | 65 K | - | 203 | 1 K | 1.09 M | - | 182 K | 58.8 K | 53.1 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.45 M | 203 | 278 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Myriad Genetics
MYGN
|
800 K | $ 4.11 | -18.29 % | $ 381 M |  USA |
 |
National Research Corporation
NRC
|
-95 K | $ 17.86 | -4.7 % | $ 400 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
288 M | $ 27.23 | 2.95 % | $ 20 B |  Niderland |
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 17.01 | -0.09 % | $ 179 M |  China |
 |
Agilent Technologies
A
|
81 M | $ 117.69 | 0.14 % | $ 35.8 B | USA |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
1.81 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
CareDx, Inc
CDNA
|
524 K | $ 20.94 | 1.16 % | $ 1.12 B | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M |  Israel |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Co-Diagnostics
CODX
|
106 K | $ 1.64 | 3.14 % | $ 2.18 M | USA |
 |
Castle Biosciences
CSTL
|
144 K | $ 24.75 | 0.61 % | $ 687 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Medpace Holdings
MEDP
|
-5.34 M | - | - | $ 12.3 B | USA |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 181.73 | -1.97 % | $ 9.01 B | USA |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
NeoGenomics
NEO
|
296 K | $ 8.89 | 0.34 % | $ 1.14 B | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | - | - | $ 19.8 B | USA |
 |
Natera
NTRA
|
9.32 M | $ 215.09 | 4.02 % | $ 21.2 B | USA |
 |
Fulgent Genetics
FLGT
|
561 K | $ 14.92 | 0.13 % | $ 451 M | USA |
 |
Personalis
PSNL
|
24 K | $ 6.07 | 9.17 % | $ 360 M | USA |
 |
Guardant Health
GH
|
-10.5 M | $ 92.25 | 3.05 % | $ 11.6 B | USA |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
Soleno Therapeutics
SLNO
|
110 K | $ 52.94 | 0.04 % | $ 2.69 B | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 124.13 | 2.32 % | $ 10.2 B |  Irlanda |
 |
Illumina
ILMN
|
-292 M | $ 142.58 | 2.52 % | $ 22.7 B | USA |
 |
Senseonics Holdings
SENS
|
-23 K | $ 5.36 | 7.2 % | $ 224 M | USA |
 |
Interpace Biosciences
IDXG
|
-252 K | - | - | $ 9.33 M | USA |
 |
QIAGEN N.V.
QGEN
|
-6.65 M | - | - | $ 10.6 B | Niderland |
 |
Thermo Fisher Scientific
TMO
|
-12 M | $ 472.95 | 1.33 % | $ 178 B | USA |
 |
Biomerica
BMRA
|
367 | $ 2.21 | 1.14 % | $ 5.08 M | USA |
 |
Trinity Biotech plc
TRIB
|
6.75 M | $ 0.6 | 0.42 % | $ 61.9 M | Irlanda |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 86.15 | 0.38 % | $ 5.81 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 256.94 | -0.08 % | $ 21.4 B | USA |
 |
Twist Bioscience Corporation
TWST
|
-903 K | $ 59.53 | 4.99 % | $ 3.56 B | USA |
 |
Celcuity
CELC
|
2.11 M | - | - | $ 6.52 B | USA |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
Neogen Corporation
NEOG
|
38.1 M | $ 9.18 | -0.97 % | $ 1.99 B | USA |
 |
Waters Corporation
WAT
|
14.3 M | $ 349.53 | 1.98 % | $ 20.8 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 189.13 | -0.9 % | $ 21 B | USA |